Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants

Document first published:
Page updated:
Topic:
Publication type:
,

In response to the public health emergency posed by COVID-19, NHS England and NHS Improvement, working with the Devolved Administrations (DAs), has established a rapid policy development process to aid clinicians in offering best care and advice to patients with, or at risk of, COVID-19 across the UK.

Summary

This document sets out the interim clinical commissioning position for passive immunisation with palivizumab against respiratory syncytial virus (RSV) in at-risk pre-term infants.

Summary

Letter from James Palmer, National Medical Director, Specialised Services, NHS England and NHS Improvement.